Kangrong Dongfang

Beijing Kangrong Dongfang Pharmaceutical Technology Development (KRDF) is a prominent Chinese Contract Research Organization (CRO) that provides comprehensive clinical trial and regulatory services. Founded in 2003 and headquartered in Beijing, the company specializes in Phase I-IV clinical trials, bioequivalence (BE) studies, and medical writing. KRDF is particularly noted for its expertise in navigating the complex regulatory environment of the National Medical Products Administration (NMPA), facilitating market entry for both domestic and international pharmaceutical products. The firm serves a diverse range of therapeutic areas, including oncology, cardiovascular disease, and infectious diseases, positioning itself as a critical bridge for drug development in the Chinese market.